Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.

Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A.

N Engl J Med. 2019 Apr 25;380(17):1597-1605. doi: 10.1056/NEJMoa1815039. Epub 2019 Apr 10.

PMID:
30969503
2.

Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation.

Jain P, Tian X, Cordes S, Chen J, Cantilena CR, Bradley C, Panjwani R, Chinian F, Keyvanfar K, Battiwalla M, Muranski P, Barrett AJ, Ito S.

Biol Blood Marrow Transplant. 2019 Feb;25(2):216-222. doi: 10.1016/j.bbmt.2018.09.037. Epub 2018 Oct 4.

PMID:
30292745
3.

Restoring antiviral immunity with adoptive transfer of ex-vivo generated T cells.

Migliori E, Chang M, Muranski P.

Curr Opin Hematol. 2018 Nov;25(6):486-493. doi: 10.1097/MOH.0000000000000461.

PMID:
30281036
4.

TGF-β-mediated enhancement of TH17 cell generation is inhibited by bone morphogenetic protein receptor 1α signaling.

Browning LM, Pietrzak M, Kuczma M, Simms CP, Kurczewska A, Refugia JM, Lowery DJ, Rempala G, Gutkin D, Ignatowicz L, Muranski P, Kraj P.

Sci Signal. 2018 Aug 28;11(545). pii: eaar2125. doi: 10.1126/scisignal.aar2125.

PMID:
30154100
5.

Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.

Aue G, Sun C, Liu D, Park JH, Pittaluga S, Tian X, Lee E, Soto S, Valdez J, Maric I, Stetler-Stevenson M, Yuan C, Nakamura Y, Muranski P, Wiestner A.

J Immunol. 2018 Oct 1;201(7):1967-1974. doi: 10.4049/jimmunol.1800570. Epub 2018 Aug 13.

PMID:
30104242
6.

Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation.

Cantilena CR, Ito S, Tian X, Jain P, Chinian F, Anandi P, Keyvanfar K, Draper D, Koklanaris E, Hauffe S, Superata J, Stroncek D, Muranski P, Barrett AJ, Battiwalla M.

Biol Blood Marrow Transplant. 2018 Mar;24(3):460-466. doi: 10.1016/j.bbmt.2017.11.028. Epub 2017 Nov 29.

7.

T cell therapies for human polyomavirus diseases.

Davies SI, Muranski P.

Cytotherapy. 2017 Nov;19(11):1302-1316. doi: 10.1016/j.jcyt.2017.08.011. Epub 2017 Sep 18. Review.

PMID:
28927823
8.

Rapamycin is highly effective in murine models of immune-mediated bone marrow failure.

Feng X, Lin Z, Sun W, Hollinger MK, Desierto MJ, Keyvanfar K, Malide D, Muranski P, Chen J, Young NS.

Haematologica. 2017 Oct;102(10):1691-1703. doi: 10.3324/haematol.2017.163675. Epub 2017 Jul 20.

9.

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia.

Jain P, Klotz J, Dunavin N, Lu K, Koklanaris E, Draper D, Superata J, Chinian F, Yu Q, Keyvanfar K, Wong S, Muranski P, Barrett AJ, Ito S, Battiwalla M.

Leuk Res Rep. 2017 Apr 13;7:40-44. doi: 10.1016/j.lrr.2017.04.003. eCollection 2017.

10.

Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.

Anandi P, Tian X, Ito S, Muranski P, Chokshi PD, Watters N, Chawla U, Hensel N, Stroncek DF, Battiwalla M, Barrett AJ.

Cytotherapy. 2017 Jun;19(6):735-743. doi: 10.1016/j.jcyt.2017.03.010. Epub 2017 Apr 7.

PMID:
28395942
11.

High angiopoietin-2 and suppression of tumorigenicity-2 levels correlate with onset of sinusoidal obstructive syndrome-implication for the utility of serial biomarker monitoring.

Nunes AT, Jain P, Kleiner DE, Shah NN, Anandi P, Chinian F, Muranski P, Battiwalla M, Barrett AJ, Ito S.

Bone Marrow Transplant. 2017 Jun;52(6):926-928. doi: 10.1038/bmt.2017.38. Epub 2017 Mar 13. No abstract available.

PMID:
28287645
12.

A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.

Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K.

Blood. 2017 Feb 9;129(6):740-758. doi: 10.1182/blood-2016-05-713347. Epub 2016 Nov 7.

13.

Improved reproducibility and quality of GvHD biomarker assay: application of multiplex microfluidic channel system.

Anandi P, Tian X, Chinian F, Cantilena CR, Dunavin N, Hensel N, Draper D, Koklanaris E, Maxwell S, Superata J, Muranski P, Battiwalla M, Paczesny S, Barrett AJ, Ito S.

Bone Marrow Transplant. 2016 Dec;51(12):1615-1616. doi: 10.1038/bmt.2016.226. Epub 2016 Sep 5. No abstract available.

PMID:
27595279
14.

Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.

Whitehill GD, Amarnath S, Muranski P, Keyvanfar K, Battiwalla M, Barrett AJ, Chinnassamy D.

Mol Ther. 2016 Sep;24(9):1655-64. doi: 10.1038/mt.2016.147. Epub 2016 Jul 6.

15.

Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.

Dumitriu B, Ito S, Feng X, Stephens N, Yunce M, Kajigaya S, Melenhorst JJ, Rios O, Scheinberg P, Chinian F, Keyvanfar K, Battiwalla M, Wu CO, Maric I, Xi L, Raffeld M, Muranski P, Townsley DM, Young NS, Barrett AJ, Scheinberg P.

Lancet Haematol. 2016 Jan;3(1):e22-9. doi: 10.1016/S2352-3026(15)00227-6. Epub 2015 Dec 17.

16.

Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia.

Hosokawa K, Muranski P, Feng X, Townsley DM, Liu B, Knickelbein J, Keyvanfar K, Dumitriu B, Ito S, Kajigaya S, Taylor JG 6th, Kaplan MJ, Nussenblatt RB, Barrett AJ, O'Shea J, Young NS.

J Immunol. 2016 Feb 15;196(4):1568-78. doi: 10.4049/jimmunol.1501739. Epub 2016 Jan 13.

17.

Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.

Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, Klebanoff CA, Ji Y, Li P, Yu Z, Whitehill GD, Clever D, Eil RL, Palmer DC, Mitra S, Rao M, Keyvanfar K, Schrump DS, Wang E, Marincola FM, Gattinoni L, Leonard WJ, Muranski P, Finkel T, Restifo NP.

Cell Metab. 2016 Jan 12;23(1):63-76. doi: 10.1016/j.cmet.2015.11.002. Epub 2015 Dec 8.

18.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP.

J Clin Invest. 2016 Jan;126(1):318-34. doi: 10.1172/JCI81217. Epub 2015 Dec 14.

19.

PPARγ antagonist attenuates mouse immune-mediated bone marrow failure by inhibition of T cell function.

Sato K, Feng X, Chen J, Li J, Muranski P, Desierto MJ, Keyvanfar K, Malide D, Kajigaya S, Young NS.

Haematologica. 2016 Jan;101(1):57-67. doi: 10.3324/haematol.2014.121632. Epub 2015 Nov 20.

20.

Identification of novel microRNA signatures linked to acquired aplastic anemia.

Hosokawa K, Muranski P, Feng X, Keyvanfar K, Townsley DM, Dumitriu B, Chen J, Kajigaya S, Taylor JG, Hourigan CS, Barrett AJ, Young NS.

Haematologica. 2015 Dec;100(12):1534-45. doi: 10.3324/haematol.2015.126128. Epub 2015 Sep 9.

21.

Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.

Ito S, Barrett AJ, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel NF, Rezvani K, Muranski P, Liu P, Larochelle A, Melenhorst JJ.

Stem Cell Res. 2015 Jan;14(1):95-104. doi: 10.1016/j.scr.2014.11.007. Epub 2014 Dec 6.

22.

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, Wang E, Marincola FM, Gattinoni L, Muranski P, Sundrud MS, Klebanoff CA, Rosenberg SA, Fearon DT, Restifo NP.

Cancer Res. 2015 Jan 15;75(2):296-305. doi: 10.1158/0008-5472.CAN-14-2277. Epub 2014 Nov 28.

23.

Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.

Jain NA, Ito S, Tian X, Kurlander R, Battiwalla M, Lu K, Savani BN, Malkovska V, Rezvani K, Le RQ, Shenoy A, Hourigan CS, Keyvanfar K, Koklanaris E, Superata J, Muranski P, Barrett AJ, Yong ASM.

Bone Marrow Transplant. 2015 Feb;50(2):189-196. doi: 10.1038/bmt.2014.249. Epub 2014 Nov 10.

24.

The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.

Jain NA, Lu K, Ito S, Muranski P, Hourigan CS, Haggerty J, Chokshi PD, Ramos C, Cho E, Cook L, Childs R, Battiwalla M, Barrett AJ.

Cytotherapy. 2014 Jul;16(7):927-33. doi: 10.1016/j.jcyt.2014.02.010. Epub 2014 May 13.

25.

An easy way to make a good anti-tumor chimeric antigen receptor T cell?

Muranski P.

Cytotherapy. 2014 May;16(5):577-8. doi: 10.1016/j.jcyt.2014.03.003. No abstract available.

PMID:
24725890
26.

Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, Chen J, Kotliarov Y, Cheung F, Xie Z, Marincola F, Tanimoto K, Battiwalla M, Olnes MJ, Perl S, Schum P, Hughes TE, Keyvanfar K, Hensel N, Muranski P, Young NS, Barrett AJ.

Mol Ther. 2014 Jul;22(7):1388-1395. doi: 10.1038/mt.2014.50. Epub 2014 Apr 1.

27.

Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells.

Kerkar SP, Chinnasamy D, Hadi N, Melenhorst J, Muranski P, Spyridonidis A, Ito S, Weber G, Yin F, Hensel N, Wang E, Marincola FM, Barrett AJ.

Immunology. 2014 Sep;143(1):96-108. doi: 10.1111/imm.12292.

28.

Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells.

Tanimoto K, Muranski P, Miner S, Fujiwara H, Kajigaya S, Keyvanfar K, Hensel N, Barrett AJ, Melenhorst JJ.

Cytotherapy. 2014 Jan;16(1):135-46. doi: 10.1016/j.jcyt.2013.08.008. Epub 2013 Oct 29.

PMID:
24176543
29.

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.

Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L.

J Clin Invest. 2013 Oct;123(10):4479-88. doi: 10.1172/JCI69589. Epub 2013 Sep 16.

30.

Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells.

Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA, Ferreyra GA, Leonardi AJ, Borman ZA, Wang J, Palmer DC, Wilhelm C, Cai R, Sun J, Napoli JL, Danner RL, Gattinoni L, Belkaid Y, Restifo NP.

J Exp Med. 2013 Sep 23;210(10):1961-76. doi: 10.1084/jem.20122508. Epub 2013 Sep 2.

31.

BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.

Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP.

Nature. 2013 Jun 27;498(7455):506-10. doi: 10.1038/nature12199. Epub 2013 Jun 2.

32.

Essentials of Th17 cell commitment and plasticity.

Muranski P, Restifo NP.

Blood. 2013 Mar 28;121(13):2402-14. doi: 10.1182/blood-2012-09-378653. Epub 2013 Jan 16. Review.

33.

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.

Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA.

Gene Ther. 2013 May;20(5):575-80. doi: 10.1038/gt.2012.75. Epub 2012 Sep 13.

34.

Th17 cells are long lived and retain a stem cell-like molecular signature.

Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP.

Immunity. 2011 Dec 23;35(6):972-85. doi: 10.1016/j.immuni.2011.09.019. Epub 2011 Dec 15.

35.

Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells.

Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P, Wang E, Schrump DS, Marincola FM, Restifo NP, Gattinoni L.

Nat Immunol. 2011 Nov 6;12(12):1230-7. doi: 10.1038/ni.2153.

36.

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G, Rosenberg SA, Restifo NP.

J Clin Invest. 2011 Dec;121(12):4746-57. doi: 10.1172/JCI58814. Epub 2011 Nov 7.

37.

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP.

Clin Cancer Res. 2011 Aug 15;17(16):5343-52. doi: 10.1158/1078-0432.CCR-11-0503. Epub 2011 Jul 7.

38.

Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP.

J Immunother. 2011 May;34(4):343-52. doi: 10.1097/CJI.0b013e3182187600.

39.

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP.

Blood. 2011 Jan 20;117(3):808-14. doi: 10.1182/blood-2010-05-286286. Epub 2010 Oct 22.

40.

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP.

Cancer Res. 2010 Sep 1;70(17):6725-34. doi: 10.1158/0008-5472.CAN-10-0735. Epub 2010 Jul 20.

41.

Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA.

J Exp Med. 2010 Mar 15;207(3):651-67. doi: 10.1084/jem.20091921. Epub 2010 Feb 15.

42.

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP.

J Exp Med. 2010 Mar 15;207(3):637-50. doi: 10.1084/jem.20091918. Epub 2010 Feb 15.

43.

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP.

J Immunother. 2010 Jan;33(1):1-7. doi: 10.1097/CJI.0b013e3181b88ffc.

44.

T helper 17 cells promote cytotoxic T cell activation in tumor immunity.

Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C.

Immunity. 2009 Nov 20;31(5):787-98. doi: 10.1016/j.immuni.2009.09.014. Epub 2009 Oct 29.

45.

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.

Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74. doi: 10.1073/pnas.0907448106. Epub 2009 Sep 24.

46.

Does IL-17 promote tumor growth?

Muranski P, Restifo NP.

Blood. 2009 Jul 9;114(2):231-2. doi: 10.1182/blood-2009-04-215541. No abstract available.

47.

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.

Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP.

Nat Med. 2009 Jul;15(7):808-13. doi: 10.1038/nm.1982. Epub 2009 Jun 14.

48.

Type 17 CD8+ T cells display enhanced antitumor immunity.

Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NP.

Blood. 2009 Jul 16;114(3):596-9. doi: 10.1182/blood-2009-02-203935. Epub 2009 May 26.

49.

Adoptive immunotherapy of cancer using CD4(+) T cells.

Muranski P, Restifo NP.

Curr Opin Immunol. 2009 Apr;21(2):200-8. doi: 10.1016/j.coi.2009.02.004. Epub 2009 Mar 13. Review.

50.

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP.

Blood. 2008 Dec 1;112(12):4746-54. doi: 10.1182/blood-2008-07-169797. Epub 2008 Sep 17.

Supplemental Content

Loading ...
Support Center